MELLITUS
Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.
MELLITUS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Medical Device
Founded:
2011-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.mellitusllc.com
Total Employee:
1+
Status:
Active
Contact:
617-758-4146
Total Funding:
13.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Apache Google Apps For Business JsDelivr PHP
Similar Organizations
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
VibeDx
VibeDx develops tools to diagnose back problems.
Current Advisors List
Current Employees Featured
Founder
Investors List
Broadview Ventures
Broadview Ventures investment in Debt Financing - Mellitus
Official Site Inspections
http://www.mellitusllc.com
- Host name: 172.67.208.252
- IP address: 172.67.208.252
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
